This page shows the latest Reata news and features for those working in and with pharma, biotech and healthcare.
Reata Pharma success in kidney disease treatment. Reata Pharmaceuticals has produced phase II results showing its bardoxolone methyl (bardoxolone) can prevent or dealy kidney failure in a rare form of chronic ... Reata collected historical eGFR data for
The pharma company will make a one-off payment of $400m to Texas, US-based Reata Pharmaceuticals for its second-generation oral antioxidant inflammation modulators (AIMs). ... For these conditions, Abbott will take 70 per cent of costs and profits, while
A similar rationale applies to the deal between Abbott and Reata where Abbott will be providing the global marketing capability outside the US. ... Platform. 480. PregLem/Richter. Corporate acquisition. . 461. Reata/Abbott. Bardoxolone for chronic
Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney disease. ... Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney
P1 . 334. Reata Pharma/Kyowa Hakko . Bardoxolone in chronic kidney disease. P2a .
More from news
Approximately 0 fully matching, plus 5 partially matching documents found.
Prior to his time at Portola, Dr Gold was head of clinical development at Reata Pharmaceuticals and before that spent 11 years at AstraZeneca.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....